BCLI Overview

Financial Update: BrainStorm Cell Therapeutics reported a net loss of approximately $2.1 million for Q3 2025, a decrease from $2.7 million in Q3 2024, with cash reserves at about $0.23 million.

NurOwn Clinical Trial Progress: The company has received FDA clearance to initiate a Phase 3b clinical trial for NurOwn, aimed at generating data to support a Biologics License Application (BLA) for ALS treatment.

Community Engagement: A Citizen Petition from the ALS community has been filed to request a renewed regulatory review of NurOwn, which BrainStorm views as a positive development reflecting interest in the therapy's potential.

Future Plans: BrainStorm plans to host a conference call in late Q4 2025 or early Q1 2026 to provide updates on the NurOwn Phase 3 program and its ongoing efforts in the ALS community.

Alto Neuroscience Investigation: Grabar Law Office is investigating claims against Alto Neuroscience, Inc. for potential breaches of fiduciary duties by its officers and directors, following allegations of misleading statements regarding the effectiveness of its treatment ALTO-100.

Brainstorm Cell Therapeutics Update: An investigation is ongoing into Brainstorm Cell Therapeutics Inc. after key allegations in a securities fraud class action survived a motion to dismiss, concerning misleading statements about FDA feedback and clinical trial safety.

Flywire Corporation Claims: Grabar Law Office is looking into Flywire Corporation for possible breaches of fiduciary duties, as a securities fraud complaint alleges the company overstated its revenue growth and downplayed negative impacts from permit and visa restrictions.

Ibotta, Inc. Allegations: Ibotta, Inc. is under investigation for potentially misleading statements made during its IPO regarding the risks associated with its contract with Kroger, which was at-will and could be canceled without warning.

Corporate Update: BrainStorm Cell Therapeutics announced the initiation of a Phase 3b clinical trial for its ALS therapy, NurOwn®, following FDA clearance, and highlighted encouraging survival data from its Expanded Access Program.

Financial Overview: The company reported a net loss of approximately $2.9 million for Q2 2025, with cash reserves of about $1.03 million, while also noting a decrease in general administrative expenses compared to the previous year.

Conference Call Announcement: BrainStorm Cell Therapeutics Inc. will hold a conference call on August 14, 2025, at 8:30 AM ET to update shareholders on its financial results for Q2 2025, featuring key executives including the CEO and COO.

Company Overview: BrainStorm specializes in adult stem cell therapies for neurodegenerative diseases, particularly ALS, and is advancing its NurOwn® platform while also developing an exosome-based technology, with recent patent allowances enhancing its intellectual property portfolio.

Stock Performance and Delisting: BrainStorm Cell Therapeutics Inc. (BCLI) shares plummeted 42.74% to $0.67 after the company announced its voluntary delisting from the Nasdaq due to non-compliance with shareholder equity requirements, although it will continue trading on the OTCQB Venture Market.

Company's Commitment: Despite the delisting, CEO Chaim Lebovits reassured shareholders that the company's mission to develop its ALS therapy, NurOwn, remains unchanged, emphasizing ongoing research and business operations are unaffected.